Immunotherapy combo for liver cancer shows early promise but trial halted

NCT ID NCT03630640

Terminated Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) given before and after a procedure called electroporation for people with advanced hepatocellular carcinoma (liver cancer) that could still be treated with curative intent. The study aimed to see if adding nivolumab could reduce the chance of cancer coming back within a year. However, the trial was terminated early after enrolling 43 participants, so the full results are not available. The approach remains experimental.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab (Opdivo)
What this could lead to: If successful, this approach could improve local control of advanced liver cancer after electroporation, potentially reducing recurrence.
What could go wrong: The trial was terminated early with only 43 participants, so results are limited. Immunotherapy can cause immune-related side effects, and the combination may not improve outcomes over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Hôpital Jean Verdier

Bondy, 93140, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.